Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > KOL Insight

KOL Insight


  • Sort by Name
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products descending
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Post-ADPD Alzheimer’s Disease KOL Interview

    $599.00

    Key Highlights BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB) BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB) MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance […]

    April 8, 2015
    Find out more

  • Post-AASLD US KOL Interview

    $599.00

    Over 95% SVR for easy-to-treat patients, and it’s one pill a day for 8-12 weeks for most. In that context, the only way you can improve up on that is to improve care for all populations, not just for easy-to-treat but the difficult-to-treat: decompensated cirrhotics, the post-transplant, and HIV co-infected patients.

    December 16, 2014
    Find out more

  • Post-AAIC KOL Interview

    $599.00

    Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

    August 6, 2014
    Find out more

  • Pneumococcal Vaccines KOL Interview

    $599.00

    Datamonitor interviewed three infectious diseases specialists to determine the physicians’ views on marketed and pipeline pneumococcal vaccines. Two physicians were based in Chicago, IL and one in the UK. The three interviews were combined into a single report.

    August 27, 2016
    Find out more

  • Pediatric Epilepsy KOL Interview – US, West

    $599.00

    A US expert in pediatric epilepsy provides insight into the approach to treating different forms of epilepsy. The key opinion leader (KOL) dives into the late-phase pipeline for epilepsy, as well as sharing insight into Epidiolex.

    February 18, 2019
    Find out more

  • Pediatric Acute Leukemias (AML/ALL) KOL Interview

    $599.00

    Highlights Current manufacturing turnaround times for CAR-T products (2-3 weeks) for ALL are not a major limitation for pediatric leukemia patients. CAR-T treatments may be more acutely toxic than transplant immediately after infusion, but patients may have fewer medium- and long-term complications. Agents that target the cell cycle (CDK inhibitors, Aurora kinase inhibitors) will likely […]

    April 1, 2015
    Find out more

  • Palbociclib for Breast Cancer

    $89.00

    Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

    February 1, 2014
    Find out more

  • Ovarian Cancer Pulse Survey

    $599.00

    Diagnostics/diagnostic techniques discussed:

    etarfolatide/folic acid, BRCA mutation testing

    May 7, 2014
    Find out more

  • Ovarian Cancer KOL Interview – US, East Coast

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

    April 1, 2020
    Find out more

  • Ovarian Cancer KOL Interview – UK

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, ofranergene obadenovec, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

    April 2, 2020
    Find out more
  • Opioids and Chronic Neuropathic Pain Management KOL Interview

    Opioids and Chronic Neuropathic Pain Management KOL Interview

    $599.00

    Biomedtracker interviewed a neurologist based in the United States who currently treats over 1000 patients with chronic neuropathic pain per year to determine his current treatment practices for indications including fibromyalgia and views on the use of opioids and abuse-deterrent opioids.

    March 9, 2017
    Find out more

  • Non-Small Cell Lung Cancer KOL Interview – NH, US

    $1,099.00

    Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

    August 30, 2018
    Find out more
  • Non-Small Cell Lung Cancer KOL Interview

    Non-Small Cell Lung Cancer KOL Interview

    $599.00

    Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.

    December 16, 2016
    Find out more

  • Non-Small Cell Lung Cancer (NSCLC) KOL Interview – US, East Coast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.

    March 23, 2020
    Find out more

  • Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.

    March 23, 2020
    Find out more
  • Non-Alcoholic Steatohepatitis (NASH) Survey

    Non-Alcoholic Steatohepatitis (NASH) Survey

    $599.00

    Datamonitor conducted a 4-question survey of 42 United States and 40 European (based in France, Germany, Italy and United Kingdom) gastroenterologists to gauge their views on late-stage clinical candidates in non-alcoholic steatohepatitis (NASH), including Ocaliva (ICPT), elafibranor (GNFTF) and selonsertib (GILD), and their projected use of these drugs if FDA-approved.

    March 9, 2017
    Find out more

  • Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

    $599.00

    Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.

    August 28, 2020
    Find out more

  • Neuromodulation KOL Interview

    $599.00

    Neuromodulation KOL Interview

     

    February 5, 2015
    Find out more

  • NASH KOL Insight Interview #2

    $599.00

    KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]

    March 4, 2014
    Find out more

  • NASH KOL Insight Interview #1

    $599.00

    The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold

    February 20, 2014
    Find out more

  • Multiple Sclerosis KOL Insight Interview

    $599.00

    Multiple Sclerosis KOL Insight Interview

    October 28, 2014
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – US, Midwest

    $599.00

    In this interview, a US-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – UK, Southwest

    $599.00

    In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – UK, London

    $599.00

    In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • Multiple Myeloma KOL Interview – US

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and critical unmet needs are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

    May 15, 2020
    Find out more

  • Multiple Myeloma KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and UK market access issues are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

    May 15, 2020
    Find out more
  • Melanoma KOL Interview – US #2

    Melanoma KOL Interview – US #2

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.

    February 25, 2022
    Find out more
  • Melanoma KOL Interview – US #1

    Melanoma KOL Interview – US #1

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.

    February 25, 2022
    Find out more

  • MDS/AML KOL Interview

    $599.00

    Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]

    April 9, 2015
    Find out more

  • Major Depressive Disorder KOL Interview – UK

    $599.00

    A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson & Johnson’s esketamine.

    December 19, 2018
    Find out more

  • Macitenan for Pulmonary Arterial Hypertension

    $89.00

    Macitentan is a novel dual endothelin receptor antagonist (ERA)

    showing sustained receptor occupancy

    March 1, 2014
    Find out more

  • Leukemia KOL Insight and Pulse Survey Bundle

    $1,099.00

    The second-generation TKIs dasatinib and nilotinib are increasingly being used as frontline therapy for CML; this expert gives imatinib only to patients with co-morbidities.

    September 8, 2017
    Find out more

  • Key Questions in Immuno-Oncology

    $1,099.00

    This KOL survey answers key questions about current immunotherapy treatments and future trends in the immuno-oncology space.

    August 8, 2018
    Find out more

  • Intersection Between Tech and Pharma KOL Interview

    $599.00

    Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.

    January 12, 2016
    Find out more

  • Inpatient Infections Pulse

    $599.00

    We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.

    October 8, 2014
    Find out more

  • Inflammatory Bowel Disease (IBD) KOL Interview – US

    $599.00

    A US gastroenterology expert dives into the treatment algorithm, critical unmet needs, and pipeline drugs for IBD, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.

    March 1, 2021
    Find out more

  • Human Papillomavirus (HPV) KOL Interview – US, Midwest

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

    January 3, 2020
    Find out more

  • Human Papillomavirus (HPV) KOL Interview – Italy

    $599.00

    A European-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

    January 3, 2020
    Find out more
  • HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

    HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

    August 10, 2021
    Find out more
  • HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

    HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

    August 10, 2021
    Find out more

  • HER2+ Breast Cancer KOL Interview – US, West Coast

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include tucatinib, margetuximab, Onzeald, SYD985, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.

    March 3, 2020
    Find out more

  • HER2+ Breast Cancer KOL Interview – UK

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include Enhertu, tucatinib, margetuximab, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.

    March 3, 2020
    Find out more

  • Hemophilia KOL Interview – US, Southeast

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, and BeneFIX, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.

    March 20, 2020
    Find out more

  • Hemophilia KOL Interview – UK

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, BeneFIX, and Eloctate, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.

    March 20, 2020
    Find out more

  • Head and Neck Cancer KOL Interview – US, Southeast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.

    April 14, 2020
    Find out more
Page 2 of 5
Page 2 of 512345
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top